We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the ... Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Show more
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by...
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement...
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: βPYXSβ), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat...
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models The PYX-201 target EDB+FN is found overexpressed...
false000178222300017822232024-02-262024-02-26 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.73 | -14.629258517 | 4.99 | 5.2 | 3.6 | 1186297 | 4.39600352 | CS |
4 | -2.24 | -34.4615384615 | 6.5 | 6.79 | 3.6 | 771556 | 5.15787555 | CS |
12 | 2.19 | 105.797101449 | 2.07 | 6.85 | 1.99 | 848582 | 4.64268406 | CS |
26 | 2.39 | 127.807486631 | 1.87 | 6.85 | 1.35 | 467285 | 4.18968353 | CS |
52 | 1.21 | 39.6721311475 | 3.05 | 6.92 | 1.35 | 1118998 | 4.24785176 | CS |
156 | -14.74 | -77.5789473684 | 19 | 19 | 1.1 | 602779 | 4.22263236 | CS |
260 | -14.74 | -77.5789473684 | 19 | 19 | 1.1 | 602779 | 4.22263236 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions